Abstract
The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 455-457 |
| Number of pages | 3 |
| Journal | American Journal of Lifestyle Medicine |
| Volume | 6 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2012 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine (miscellaneous)
- Health Policy
- Public Health, Environmental and Occupational Health
Cite this
Medication Use for Hypercholesterolemia in the Pediatric Population. / Lenz, Thomas L.; Larson, Jessica C.
In: American Journal of Lifestyle Medicine, Vol. 6, No. 6, 11.2012, p. 455-457.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Medication Use for Hypercholesterolemia in the Pediatric Population
AU - Lenz, Thomas L.
AU - Larson, Jessica C.
PY - 2012/11
Y1 - 2012/11
N2 - The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.
AB - The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.
UR - http://www.scopus.com/inward/record.url?scp=84867735459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867735459&partnerID=8YFLogxK
U2 - 10.1177/1559827612455625
DO - 10.1177/1559827612455625
M3 - Article
VL - 6
SP - 455
EP - 457
JO - American Journal of Lifestyle Medicine
JF - American Journal of Lifestyle Medicine
SN - 1559-8276
IS - 6
ER -